187669-62-1

Basic information

• Product Name: 1-(4-Trifluoromethoxyphenyl)piperazine
• Synonyms: 1-(4-Trifluoromethoxyphenyl)piperazine;4-(4-Trifluoromethoxyphenyl)piperazine
• CAS NO: 187669-62-1
• Molecular Formula: C₁₁H₁₃F₃N₂O
• Molecular Weight: 246.23
• Product Categories: pharmacetical
• Mol File: 187669-62-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 308.5°Cat760mmHg
• Flash Point: 140.4°C
• Appearance: /
• Density: 1.242g/cm³
• Vapor Pressure: 0.000677mmHg at 25°C
• Refractive Index: 1.486
• CAS DataBase Reference: 1-(4-Trifluoromethoxyphenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Trifluoromethoxyphenyl)piperazine(187669-62-1)
• EPA Substance Registry System: 1-(4-Trifluoromethoxyphenyl)piperazine(187669-62-1)

Safety Data

• Hazardous Substances Data: 187669-62-1(Hazardous Substances Data)

Usage

General Description

1-(4-Trifluoromethoxyphenyl)piperazine, also known as TFMPP, is a chemical compound that belongs to the piperazine class of chemicals. It is a psychoactive drug that has been used as a recreational drug and as an ingredient in herbal smoking blends. TFMPP is known to produce effects such as mild stimulation, euphoria, and slight hallucinogenic effects, and it has been marketed as a legal alternative to MDMA. However, its use has been associated with adverse effects such as increased heart rate, nausea, and anxiety, and it has been banned in many countries due to its potential for abuse and harm. TFMPP is classified as a Schedule I controlled substance in the United States, making its manufacture, distribution, and possession illegal.

InChI:InChI=1/C11H13F3N2O/c12-11(13,14)17-10-3-1-9(2-4-10)16-7-5-15-6-8-16/h1-4,15H,5-8H2

Upstream product

• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 
• 461-82-5 4-(trifluoromethoxy)aniline 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 490030-45-0 tert-butyl 4-(4-(trifluoromethyl)-phenyl)-piperazine-1-carboxylate 
• 490030-46-1 1-(4-(trifluoromethoxy)phenyl)piperazine hydrochloride 
• 110-85-0 piperazine 

Downstream Products

• 681032-13-3 (S)-1-(2-chloro-4-nitroimidazol-1-yl)-2-methyl-3-[4-(4-trifluoromethoxyphenyl)piperazin-1-yl]propan-2-ol 
• 1231170-13-0 1-(2,2-dimethyl-[1,3]dioxan-5-ylmethyl)-4-(4-trifluoromethoxyphenyl)piperazine 
• 1263417-13-5 (6S)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl 4-[4-(trifluoromethoxy)phenyl]-piperazine-1-carboxylate 

Relevant articles and documents

Nitroimidazole compound as well as preparation method and application thereof

The invention discloses a novel nitroimidazole compound as well as a preparation method and application thereof. The nitroimidazole compound has a general formula (I) shown in the specification.

Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors

The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.

NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION

Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's disease.